|
|||||
|
|
Examination of the efficacy of olanexidine gluconate for surgical site infections in colorectal cancer elective surgery |
|
| Institution: | 1. Department of Surgery, Japan Community Health Care Organization Sagamino Hospital, Sagamihara, Japan;2. First Department of Surgery, Dokkyo Medical University, Shimotsuga, Japan;1. Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan;2. Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan;3. Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan;1. Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan;2. Department of Internal Medicine, Cardiology, Fukuoka University Hospital, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan;3. Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8640, Japan;4. Division of Pathology, Saiseikai Fukuoka General Hospital, 1-3-46 Tenjin, Chuo-ku, Fukuoka, 810-0001, Japan;1. Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT, 06510, USA;2. Yale School of Medicine, 367 Cedar St, New Haven, CT, 06510, USA;3. Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, USA;4. Yale Center for Analytical Science, Yale School of Public Health, PO Box 208034, New Haven, CT, 06520, USA;5. Department of Pharmacy, Yale New Haven Health, 20 York St, New Haven, CT, 06510, USA;6. Section of Hematology, Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT, 06510, USA;7. Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT, 06510, USA;1. Specialist for Otorhinolaryngology, Allergist, Schorndorf, Germany;2. Clinical Development, ALK-Abelló Arzneimittel GmbH, Hamburg, Germany;3. Specialist for Otorhinolaryngology, Allergist, Dresden, Germany;4. Schwab and Schwab Interdisciplinary Therapy Center, Munich, Germany;5. Specialist for Otorhinolaryngology, Allergist, Munich, Germany;6. Institut für Angewandte Statistik GmbH, Bielefeld, Germany;7. Medical Department, ALK-Abelló Arzneimittel GmbH, Hamburg, Germany;8. Clinic for Otorhinolaryngology, Universitätsklinikum Carl Gustav Carus, Dresden, Germany |
| Abstract: | IntroductionThe preoperative skin antiseptic, olanexidine gluconate (OLG), which has been available in Japan since 2015, is also known to be effective against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and Pseudomonas aeruginosa. This study attempted to clarify OLG efficacy against surgical site infections and antiseptic-related adverse events as compared to conventionally used povidone iodine (PVP–I).MethodsPropensity score matching was performed on 307 patients who underwent surgery for colorectal tumors at our hospital. All 116 cases (58 PVP-I cases, 58 OLG cases) who were diagnosed with colorectal cancer were included. We examined surgical site infection rate after disinfection using PVP-I and OLG, length of hospitalization stay (days) after surgery, adverse events associated with antiseptics, and additional medical costs associated with adverse events caused by antiseptics.ResultsThe surgical site infection rate was 8.6% in both the PVP-I and OLG groups, with no significant difference observed. The number of postoperative hospitalization days in the PVP-I group was 12.9 (±6.9) days and 16.4 (±14.6) days in the OLG group, which exhibited no significant difference (p = 0.10). Although no complications due to antiseptics were observed in the PVP-I group, skin-related side effects were observed in 8 patients (13.8%) in the OLG group. The median additional medical cost was 730 120–1823] yen.ConclusionsOLG was as effective as the conventional PVP-I for surgical site infections during colorectal cancer elective surgery. However, significantly higher skin disorders occurred in OLG, thereby making it necessary to evaluate antiseptic use in conjunction with patient burden. |
| Keywords: | Olanexidine gluconate Surgical site infection Colorectal cancer ACS/SIS"} {"#name":"keyword" "$":{"id":"kwrd0030"} "$$":[{"#name":"text" "_":"American College of Surgeons and Surgical Infection Society CDC"} {"#name":"keyword" "$":{"id":"kwrd0040"} "$$":[{"#name":"text" "_":"the Centers for Disease Control and Prevention CHG"} {"#name":"keyword" "$":{"id":"kwrd0050"} "$$":[{"#name":"text" "_":"chlorhexidine gluconate ERAS"} {"#name":"keyword" "$":{"id":"kwrd0060"} "$$":[{"#name":"text" "_":"enhanced recovery after surgery iSSI"} {"#name":"keyword" "$":{"id":"kwrd0070"} "$$":[{"#name":"text" "_":"inciisional SSI JANIS"} {"#name":"keyword" "$":{"id":"kwrd0080"} "$$":[{"#name":"text" "_":"Japan Nosocomial Infections Surveillance JSSI"} {"#name":"keyword" "$":{"id":"kwrd0090"} "$$":[{"#name":"text" "_":"Japan Society for Surgical Infection NICE"} {"#name":"keyword" "$":{"id":"kwrd0100"} "$$":[{"#name":"text" "_":"National Institute for Health and Care Excellence OLG"} {"#name":"keyword" "$":{"id":"kwrd0110"} "$$":[{"#name":"text" "_":"Olanedine o/sSSI"} {"#name":"keyword" "$":{"id":"kwrd0120"} "$$":[{"#name":"text" "_":"organ/space SSI PSM"} {"#name":"keyword" "$":{"id":"kwrd0130"} "$$":[{"#name":"text" "_":"propensity score matching PVP-I"} {"#name":"keyword" "$":{"id":"kwrd0140"} "$$":[{"#name":"text" "_":"povidone iodine ROC-AUC"} {"#name":"keyword" "$":{"id":"kwrd0150"} "$$":[{"#name":"text" "_":"area under the receiver operating characteristic curve SSI"} {"#name":"keyword" "$":{"id":"kwrd0160"} "$$":[{"#name":"text" "_":"Surgical site infection WHO"} {"#name":"keyword" "$":{"id":"kwrd0170"} "$$":[{"#name":"text" "_":"World Health Organization |
| 本文献已被 ScienceDirect 等数据库收录！ | |